NAKA plunged 99.32% in 280 days, erasing $23.64 billion after heavy Bitcoin purchases near record highs. Nakamoto Inc. bought 5,398 BTC for nearly $118,000, nowNAKA plunged 99.32% in 280 days, erasing $23.64 billion after heavy Bitcoin purchases near record highs. Nakamoto Inc. bought 5,398 BTC for nearly $118,000, now

$23.6B Erased as NAKA Crashes 99% After Bitcoin Bet

2026/02/22 22:45
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
  • NAKA plunged 99.32% in 280 days, erasing $23.64 billion after heavy Bitcoin purchases near record highs.
  • Nakamoto Inc. bought 5,398 BTC for nearly $118,000, now carrying about $270 million in unrealized losses.
  • Falling trading volumes and weak sentiment followed the crash, while Bitcoin price movements remain central to recovery hopes.

Nakamoto Inc.’s Bitcoin treasury strategy led to a steep collapse, with NAKA falling 99.32% over 280 days and erasing $23.64 billion in market value as of February 21, 2026. The company bought 5,398 BTC near $118,000, now showing $270 million in unrealized losses, raising concerns about concentrated Bitcoin exposure and treasury risk management.

Bitcoin Bet Near Market Highs

Nakamoto Inc. increased its Bitcoin holdings when prices traded near record levels. The purchase of 5,398 BTC was positioned as a long-term treasury move. However, Bitcoin prices later retreated, and the value of the holdings declined. As Bitcoin corrected, NAKA entered a prolonged bearish phase. 

Market data shows the token lost value steadily over 280 days. The fall erased nearly the company’s entire market capitalization. On-chain activity during the period indicated increased selling pressure. Large token holders reduced positions during key downturns. Trading volumes spiked during sell-offs and later weakened as prices stabilized at lower levels.

The company has not announced a reversal of its Bitcoin treasury approach. Public data shows the unrealized losses remain tied to the Bitcoin position. The downturn mirrors earlier crypto cycles where assets fell more than 90% from peaks.

Market Reaction and Trading Activity

The 99.32% decline has affected broader crypto sentiment. Social media activity and trading discussions increased as the losses deepened. Fear-based indicators moved higher during the steepest drops. Daily trading volumes in NAKA fell as the price collapsed. 

Lower volumes often signal reduced participation from retail and institutional traders. Exchange data suggests activity dropped from peak levels seen during earlier rallies. Market participants are comparing the event to prior crypto market crashes. Some traders are monitoring technical indicators such as relative strength index levels below 30. 

These levels are often linked to oversold conditions. Bitcoin price movements remain central to the token’s outlook. Traders are watching key Bitcoin support zones for stability. Any sustained recovery in Bitcoin could affect related assets, including NAKA.

Broader Crypto and Cross Market Signals

The crash has also influenced discussions around corporate Bitcoin strategies. Firms that hold large Bitcoin reserves face exposure to price volatility. Concentrated positions can amplify balance sheet swings during corrections. Some investors are reviewing correlations between crypto tokens and technology equities. 

Risk appetite often shifts between digital assets and growth stocks. Market rotations have been observed during previous crypto downturns.

Other blockchain and AI-linked tokens have seen price pressure during the same period. However, performance varies based on project fundamentals and liquidity levels. 

Market participants continue to track institutional flows and fund allocations. The $23.6B Erased: Inside NAKA’s Bitcoin Treasury Disaster reflects the effect of timing and exposure in volatile markets. The token’s 99.32% fall over 280 days stands as one of the steepest declines among major crypto-linked projects in 2026.

The post $23.6B Erased as NAKA Crashes 99% After Bitcoin Bet appeared first on Live Bitcoin News.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09